DE69331331D1 - Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide - Google Patents

Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide

Info

Publication number
DE69331331D1
DE69331331D1 DE69331331T DE69331331T DE69331331D1 DE 69331331 D1 DE69331331 D1 DE 69331331D1 DE 69331331 T DE69331331 T DE 69331331T DE 69331331 T DE69331331 T DE 69331331T DE 69331331 D1 DE69331331 D1 DE 69331331D1
Authority
DE
Germany
Prior art keywords
binding peptides
inhibitoric
tolerogenic
immuno
carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69331331T
Other languages
English (en)
Other versions
DE69331331T2 (de
Inventor
D Heerze
D Armstrong
Richard Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALBERTA RESEARCH COUNCIL INC., EDMONTON, ALBERTA,
Original Assignee
Alberta Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/995,503 external-priority patent/US5453272A/en
Application filed by Alberta Research Council filed Critical Alberta Research Council
Application granted granted Critical
Publication of DE69331331D1 publication Critical patent/DE69331331D1/de
Publication of DE69331331T2 publication Critical patent/DE69331331T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
DE69331331T 1992-10-02 1993-10-04 Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide Expired - Fee Related DE69331331T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95604392A 1992-10-02 1992-10-02
US07/995,503 US5453272A (en) 1992-10-02 1992-12-21 Lectin derived carbohydrate binding-peptide
PCT/CA1993/000415 WO1994007517A1 (en) 1992-10-02 1993-10-04 Anti-inflammatory tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides

Publications (2)

Publication Number Publication Date
DE69331331D1 true DE69331331D1 (de) 2002-01-24
DE69331331T2 DE69331331T2 (de) 2002-08-14

Family

ID=27130371

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69331331T Expired - Fee Related DE69331331T2 (de) 1992-10-02 1993-10-04 Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide

Country Status (9)

Country Link
US (5) US5833990A (de)
EP (1) EP0666758B1 (de)
JP (1) JPH08501569A (de)
AT (1) ATE210452T1 (de)
AU (1) AU686116B2 (de)
CA (1) CA2145881C (de)
DE (1) DE69331331T2 (de)
ES (1) ES2169724T3 (de)
WO (1) WO1994007517A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501569A (ja) 1992-10-02 1996-02-20 アルバータ リサーチ カウンスル 糖質結合ペプチドの抗炎症性、免疫寛容原性、および免疫阻害性
JPH07101977A (ja) * 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
IL111866A (en) * 1994-12-04 2005-03-20 Yeda Res & Dev Pharmaceutical compositions comprising the b-oligomer of pertussis toxin
AU3665699A (en) * 1998-04-27 1999-11-16 Biocrystal Limited Compositions and methods for tolerization in immune complex-mediated disease progression
AU3239400A (en) * 1999-02-22 2000-09-04 University Of Iowa Research Foundation, The Method for inhibiting inflammatory responses
KR100428469B1 (ko) * 2001-04-17 2004-04-27 한국과학기술연구원 강한 결합력을 가지는 당 특이적 펩타이드 및 그의 제조방법
US20030033413A1 (en) * 2001-06-19 2003-02-13 Willson Alan N. Mobile wireless local area network
US20050026866A1 (en) * 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
US20040072992A1 (en) * 2002-08-30 2004-04-15 Sachiko Machida Novel peptide capable of specifically acting on biological membrane
EP1746902A4 (de) * 2004-05-05 2007-06-13 Univ Northeastern Multilektin-affiniätschromatografie und verwendung dafür
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
US9169327B2 (en) 2008-03-12 2015-10-27 Rowan University Targeting of podoplanin with lectin for use in the prevention and treatment of cancer
US9066894B2 (en) 2008-09-12 2015-06-30 University Court Of The University Of St. Andrews Carbohydrate binding molecules
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN106102776B (zh) 2014-01-24 2020-02-14 圣安德鲁斯大学董事会 免疫调节化合物
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
BR112021004792A2 (pt) * 2018-09-16 2021-08-03 Unichem Laboratories Ltd proteína para tratamento de doenças inflamatórias

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61165334A (ja) * 1984-08-03 1986-07-26 メデイサ−チ、エス、ア− ウイルスの感染活性の抑制方法および組成物
US4742046A (en) * 1984-08-03 1988-05-03 Medisearch S.A. Methods and compositions for inhibiting the infectious activity of viruses
US5157023A (en) * 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US5244657A (en) * 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
AU631351B2 (en) * 1988-04-20 1992-11-26 Massachusetts Health Research Institute, Inc. (Mhri) Pertussis toxoid vaccine
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
DK0436726T3 (da) * 1989-08-03 1993-12-27 Eisai Co Ltd Fotostabil oftalmisk opløsning og fremgangsmåde til fremstilling deraf
DE3926912A1 (de) * 1989-08-16 1991-02-21 Bosch Gmbh Robert Elektromagnetischer drehsteller
AU644828B2 (en) 1989-11-29 1993-12-23 Smithkline Beecham Biologicals (Sa) Novel vaccine
JPH05503512A (ja) * 1989-11-29 1993-06-10 ブリガム・アンド・ウイメンズ・ホスピタル 白血球接着阻害因子としての［ａｌａ　ｉｌ―８］↓７↓７
US5196511A (en) * 1989-12-01 1993-03-23 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
WO1991019501A1 (en) * 1990-06-15 1991-12-26 Cytel Corporation Intercellular adhesion mediators
WO1992001718A2 (en) 1990-07-17 1992-02-06 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides and ligand for gmp-140
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
NZ240316A (en) * 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
BR9106995A (pt) * 1990-11-23 1993-08-24 Gen Hospital Corp Inibicao de interacoes proteina-carboidrato com adesao celular
WO1992011612A1 (en) * 1990-12-21 1992-07-09 Minnesota Mining And Manufacturing Company Two-channel xor bar code and optical reader
WO1992016612A2 (en) * 1991-03-11 1992-10-01 New England Medical Center Hospitals, Inc. Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component
JPH06507639A (ja) * 1991-05-03 1994-09-01 ザ ロックフェラー ユニバーシティ セレクチンとｂ百日咳毒素の間のアミノ酸シーケンスの相同性−それから誘導されるペプチド、それに対する抗体、薬剤組成物
US5374655A (en) * 1991-06-10 1994-12-20 Alberta Research Council Methods for the synthesis of monofucosylated oligosaccharides terminating in di-N-acetyllactosaminyl structures
WO1993018782A1 (en) * 1992-03-20 1993-09-30 Cor Therapeutics, Inc. Glycosylation-mediated inhibition of factor x
US5440015A (en) * 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
JPH08501569A (ja) * 1992-10-02 1996-02-20 アルバータ リサーチ カウンスル 糖質結合ペプチドの抗炎症性、免疫寛容原性、および免疫阻害性
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
US5496934A (en) * 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
US5856122A (en) * 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
IL111866A (en) * 1994-12-04 2005-03-20 Yeda Res & Dev Pharmaceutical compositions comprising the b-oligomer of pertussis toxin
US5858965A (en) * 1994-12-04 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions for the treatment of autoimmune diseases comprising the B-oligomer of pertussis toxin or its subunits

Also Published As

Publication number Publication date
US5833990A (en) 1998-11-10
US20020054880A1 (en) 2002-05-09
EP0666758B1 (de) 2001-12-12
US6245883B1 (en) 2001-06-12
ATE210452T1 (de) 2001-12-15
CA2145881A1 (en) 1994-04-14
ES2169724T3 (es) 2002-07-16
US5747040A (en) 1998-05-05
WO1994007517A1 (en) 1994-04-14
DE69331331T2 (de) 2002-08-14
AU686116B2 (en) 1998-02-05
AU5105693A (en) 1994-04-26
JPH08501569A (ja) 1996-02-20
US5736143A (en) 1998-04-07
CA2145881C (en) 2000-12-19
EP0666758A1 (de) 1995-08-16

Similar Documents

Publication Publication Date Title
DE69331331D1 (de) Entzündungshemmende tolerogene und immunoinhibitorische eigenschaften von karbohydrate bindende peptide
IT8367525A0 (it) Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
TR199901571T2 (xx) T�berk�lozun imm�noterapi te�hisi i�in bile�ikler ve y�ntemler.
GR3031919T3 (en) PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES.
TR199800411T1 (xx) T�berk�lozun te�hisi ve imm�noterapi yolu ile �nlenmesine mahsus y�ntemler ve bile�ikler.
GR1001550B (el) Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ.
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
AR053063A2 (es) Proteina sustancialmente purificada y composicion farmaceutica que la comprende
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
EP0997477A3 (de) MHC-Komplexe und ihre Verwendung
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
IT1244548B (it) Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche
ATE193022T1 (de) Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
DE68927379T2 (de) Plättchen blockierende peptide
DE68925275T2 (de) Endotoxin-bindeprotein und dessen verwendung
DE69317435T2 (de) Entzündungshemmende tolerogene und inmonoinhibitorische eigenschaften von karbohyhydrate bindenden peptiden
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
HUP9904199A1 (hu) Egyláncú anti-p53 antitest fragmentumok és alkalmazásuk
ITMI930456A0 (it) Vettore ricombinante e suo impiego per la preparazione esocellulare di anticorpi in forma di singola molecola da bacillus subtilis
ATE316574T1 (de) Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen
DK0639225T3 (da) Nye polypeptider og peptider, nucleinsyrer, der koder for dem, og deres anvendelse i området tumorterapi, inflammation eller immunologi

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ALBERTA RESEARCH COUNCIL INC., EDMONTON, ALBERTA,

8339 Ceased/non-payment of the annual fee